報價延遲最少15分鐘:2025/08/25 12:27 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
55.87 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
3.27/5.40
|
|
企業價值
3.64B
|
| 資產負債 |
|
每股賬面淨值
18.31
|
| 現金流量 |
|
現金流量率
0.08
|
| 損益表 |
|
收益
1.36B
|
|
每股收益
25.72
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/25 12:27 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, thecompany operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. |
